A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D
Keywords: Alisertib; Aurora kinase; Uterine leiomyosarcoma;